OR WAIT null SECS
ALA Spokesperson and professor at Baylor College of Medicine.
November 07, 2026
Video
IL-33-targeted therapy may reach most patients with COPD regardless of eosinophil count, but questions remain about how drugs act on its 2 forms.
November 06, 2026
Article
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
IL-33 has 2 forms in COPD: oxidized IL-33 drives mucus dysfunction, while reduced IL-33 recruits inflammatory cells, with implications for mucus plugging.
November 14, 2025
COPD is not a complex disease, Polverino explains. It's only complex to treat because of limited understanding.